MAIA Biotechnology Inc

Financials

Total assets 12.02 M7.57 M10.16 M9.7 M Total liabilities 3.51 M7.09 M6.52 M7.33 M Total equity 8.51 M477.51 K3.63 M2.38 M Total liabilities & shareholders' equities 12.02 M7.57 M10.16 M9.7 M Total debt ———— Net debt ————

MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.

News

MAIA Biotechnology shares drop 29% on discounted stock offering

Vitoc Vlad, CEO of Maia Biotechnology, buys $10k in shares

Vlad Vitoc, Maia Biotech CEO, buys $79,848 in Maia stock

Vitoc Vlad buys MAIA biotechnology (MAIA) shares worth $79,848

Luput Cristian, director at Maia Biotechnology, buys $41,845 in shares

Smith Stan, MAIA Biotechnology director, buys $15,582 in shares

Luput Cristian, director at Maia Biotechnology, buys $9,785 in shares

Maia Biotech CEO Vitoc Vlad buys $10k in company stock

MAIA Biotechnology raises $736,600 in private placement

Maia Biotechnology to issue 440,503 shares after warrant exercise at reduced price

Maia Biotechnology presents Phase 2 THIO-101 trial data at lung cancer conference

Maia Biotechnology stock soars after FDA grants Fast Track designation